Drug intelligence / Profile preview

Xinshukang Tablets

Development stage: Unknown
Lead developer: Hebei
Administration: Oral

Overview

Xinshukang Tablets is a Traditional Chinese Medicine (TCM) developed by Tangshan Longshan Pharmaceutical for the treatment of cardiovascular conditions. It is specifically indicated for patients with coronary artery disease and angina pectoris who exhibit the TCM pattern of 'Qi deficiency and blood stasis.' The formulation is designed to tonify Qi and promote blood circulation to resolve stasis, thereby improving myocardial blood supply and reducing the frequency and severity of angina episodes. It has been evaluated in Phase 2 clinical trials in China to assess its efficacy and safety as a therapeutic intervention for stable angina.

Brand names: Xinshukang Tablets
Other names: Xinshukang Pian

Beyond the preview

Go deeper on Xinshukang Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinshukang Tablets.

Explore the full profile